North American myocardial infarction market is estimated to grow significantly at a CAGR of around 6.6% during the forecast period. North America contributes the highest share in the global myocardial infarction treatment market owing to the highest adoption devices and surgeries that are required for the treatment of MI. In the US alone, around 0.6 million people lose their life due to heart diseases, according to the WHO, the incidence & prevalence rate of heart attack are the highest in North America which is responsible for 0.7 million fatalities each year. According to the Heart & Stroke Foundation, in Canada alone, 1.6 million fatalities occur every year due to stroke and at least 1.3 million Canadians live with heart disease. Moreover, the growing CVD, CHD, stroke and other heart diseases, highest healthcare spending, technological advancement and adoption of hybrid operating rooms and minimally invasive surgeries are the key drivers of the MI treatment market in the region.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-american-myocardial-infarction-market
The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.
The companies which are contributing to the growth of the North American myocardial infarction market include Abbott Laboratories Inc., Johnson & Johnson Services Inc., Mylan N.V., Pfizer Inc., Bayer AG, and Novartis AG. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in June 2019, Abbott Laboratories Inc. acquired St. Jude Medical, a medical device provider. This acquisition was aimed to take leverage of St. Jude’s product portfolio that includes Ellipse VR, Ellipse Dual-Chamber ICD, Accent SR RF, Accent RF, and many other devices. Additionally, this acquisition was aimed to complement Abbott Laboratories Inc.’s cardiovascular business segment.
North American Myocardial Infarction Market Segmentation
By Type
- Non-ST-elevation myocardial infarction (NSTEMI)
- ST-elevation myocardial infarction (STEMI)
- Silent Heart Attacks
By Device
- Left Ventricular Assist Device (LVAD)
- Pacemaker
- Catheters
- Implantable Cardioverter-Defibrillator (ICD)
- Others (Stent Graft)
By Diagnosis
- Electrocardiography (ECG)
- Chest X-Ray
- Computed Tomography (CT Scan)
- Echocardiography
- Others (Blood Test)
By Treatment
- Medication
- Analgesics
- Thrombolytic
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Others (Beta-Adrenergic Blockers)
- Surgery
- Angioplasty
- Bypass Surgery
- Heart Transplant
By End-User
- Hospital & Clinics
- Ambulatory Surgical Centers
- Research Institutes
A full report of North American Myocardial Infarction Market available @ https://www.omrglobal.com/industry-reports/north-american-myocardial-infarction-market
North American Myocardial Infarction Market Regional Analysis
- United States
- Canada
